Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

This is a multicenter, open label, non-inferiority, randomized controlled clinical study. The aim of this study is to evaluate the efficacy and safety of a pegylated liposomal doxorubicin + cyclophosphamide followed by docetaxel plus trastuzumab and pertuzumab (PLD + C + HP followed by THP) regimen compared with a docetaxel + carboplatin plus trastuzumab and pertuzumab (TCbHP) regimen in the neoadjuvant treatment of HER-2-positive breast cancer.

Trial Details

NCT ID

NCT05159193

Phase

PHASE3

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

pegylated liposomal doxorubicin (PLD)
cyclophosphamide (C)
trastuzumab (H)
pertuzumab (P)
docetaxel (T)
carboplatin (Cb)

Locations (sample)

Guandong, Guangdong, China

Key Eligibility Criteria

Female patients aged from 18 to 70 years old;
Histologically confirmed as invasive breast cancer and without previous treatment.;
HER-2 Positive (defined by IHC 3+ or ISH positive);
Tumor \> 2cm;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →